An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global…

PTC Therapeutics

PTC, partner Roche to kick-start PhII SMA study; SMA Type 1 test on the horizon

Small cap PTC tumbles as FDA rejects it again in Duchenne

NICE gives PTC, NHS more time to agree on Duchenne drug price

A PhIII flop, spurned by FDA, but NICE OKs PTC’s Duchenne drug